Report #2863297

Received Oct 6, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 55 yrs
State: DE
Recovered: Unknown
Vaccinated: Sep 17, 2025
Onset: Sep 17, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

received the first dose of SHINGRIX in 2020 and second dose of SHNGRIX yesterday, 17 September 2025; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too long in a 55-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (1st dose received on an unknown date in 2020). On 17-SEP-2025, the patient received the 2nd dose of Shingrix. On 17-SEP-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: received the first dose of SHINGRIX in 2020 and second dose of SHNGRIX yesterday, 17 September 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 18-SEP-2025 The patient received the first dose of Shingrix in 2020. The patient received the second dose of Shingrix on 17 September 2025.